^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | SAB298 (SRC-family kinase (SFK) inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel anti-melanoma SRC-family kinase inhibitor
Excerpt:
Three-way Kruskal-Wallis analysis of the dot-plot display Figure 2D) showed that the difference in the levels of response to SAB298 between the double-WT and NRAS-mutant melanoma cells were statistically significant, p-value = 0.002985.
DOI:
10.18632/oncotarget.26787
